Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312076208> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4312076208 abstract "The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 (SARS-CoV-2) virus has created enormous public health and economic crises. The SARS-CoV-2 spike protein binds to its host receptor, human angiotensin-converting enzyme 2 (hACE2), through its receptor binding domain (RBD) and is proteolytically activated by human protease TMPRSS2 to process the SARS-CoV-2 spike protein to facilitate host cell entry. To identify new candidate drugs to inhibit binding of the RBD to hACE2 (the first step of virus entry), we used in silico screening (Phase VS from Schrӧdinger) to predict the RBD binding site and energetics for molecules in the ZINC FDA approved Drug Bank database (1,657 drugs), which includes clinical trial drugs approved by FDA. Using a pharmacophore (1 acceptor, 1 donor, 3 negatively charged, 1 positively charged) derived from the 2.5-Å X-ray structure SARS-CoV-2 RBD complexed with hACE2 (PDB ID: 6LZG), we found 29 unique hits. To refine the binding energies and bonding sites, we applied our DarwinDock complete sampling method, predicting that 4 of these 29 should bind strongly to the RBD site. Next, we tested 3 of these experimentally using FLOWER, a label-free optical whispering gallery mode sensing technique that can measure ligand-receptor binding affinities down to attomolar levels. We measure that methotrexate (MTX) and Diethylenetriamine pentaacetate (DTPA) bind with an inhibitory constant (Ki) of 0.2 pM in Tricine buffer, which is 1.832 million fold increase in binding strength compared to hACE2 (Kd: 366.4 nM). We then tested these ligands against common mutations: alpha, delta, and omicron. Our measured binding studies demonstrate that MTX provides inhibition against all four variants of SARS-coV-2. Indeed, the clinical and experimental data have shown that humans taking WT MTX are protected against infection by SARS-CoV-2." @default.
- W4312076208 created "2023-01-04" @default.
- W4312076208 creator A5001343963 @default.
- W4312076208 creator A5035627473 @default.
- W4312076208 creator A5048683724 @default.
- W4312076208 creator A5053622077 @default.
- W4312076208 creator A5066453320 @default.
- W4312076208 creator A5082889545 @default.
- W4312076208 creator A5083711861 @default.
- W4312076208 date "2022-12-21" @default.
- W4312076208 modified "2023-09-24" @default.
- W4312076208 title "Prediction and experimental validation of drug candidates that bind specifically to the SARS-CoV-2 receptor-binding domain to prevent entry via Angiotensin-converting enzyme 2 (ACE2)" @default.
- W4312076208 doi "https://doi.org/10.26434/chemrxiv-2022-nrhzz" @default.
- W4312076208 hasPublicationYear "2022" @default.
- W4312076208 type Work @default.
- W4312076208 citedByCount "0" @default.
- W4312076208 crossrefType "posted-content" @default.
- W4312076208 hasAuthorship W4312076208A5001343963 @default.
- W4312076208 hasAuthorship W4312076208A5035627473 @default.
- W4312076208 hasAuthorship W4312076208A5048683724 @default.
- W4312076208 hasAuthorship W4312076208A5053622077 @default.
- W4312076208 hasAuthorship W4312076208A5066453320 @default.
- W4312076208 hasAuthorship W4312076208A5082889545 @default.
- W4312076208 hasAuthorship W4312076208A5083711861 @default.
- W4312076208 hasBestOaLocation W43120762081 @default.
- W4312076208 hasConcept C107824862 @default.
- W4312076208 hasConcept C12554922 @default.
- W4312076208 hasConcept C142724271 @default.
- W4312076208 hasConcept C170493617 @default.
- W4312076208 hasConcept C181199279 @default.
- W4312076208 hasConcept C185592680 @default.
- W4312076208 hasConcept C2775946041 @default.
- W4312076208 hasConcept C2776714187 @default.
- W4312076208 hasConcept C2779134260 @default.
- W4312076208 hasConcept C3008058167 @default.
- W4312076208 hasConcept C51639874 @default.
- W4312076208 hasConcept C524204448 @default.
- W4312076208 hasConcept C55493867 @default.
- W4312076208 hasConcept C65556437 @default.
- W4312076208 hasConcept C71924100 @default.
- W4312076208 hasConcept C86803240 @default.
- W4312076208 hasConceptScore W4312076208C107824862 @default.
- W4312076208 hasConceptScore W4312076208C12554922 @default.
- W4312076208 hasConceptScore W4312076208C142724271 @default.
- W4312076208 hasConceptScore W4312076208C170493617 @default.
- W4312076208 hasConceptScore W4312076208C181199279 @default.
- W4312076208 hasConceptScore W4312076208C185592680 @default.
- W4312076208 hasConceptScore W4312076208C2775946041 @default.
- W4312076208 hasConceptScore W4312076208C2776714187 @default.
- W4312076208 hasConceptScore W4312076208C2779134260 @default.
- W4312076208 hasConceptScore W4312076208C3008058167 @default.
- W4312076208 hasConceptScore W4312076208C51639874 @default.
- W4312076208 hasConceptScore W4312076208C524204448 @default.
- W4312076208 hasConceptScore W4312076208C55493867 @default.
- W4312076208 hasConceptScore W4312076208C65556437 @default.
- W4312076208 hasConceptScore W4312076208C71924100 @default.
- W4312076208 hasConceptScore W4312076208C86803240 @default.
- W4312076208 hasFunder F4320332161 @default.
- W4312076208 hasLocation W43120762081 @default.
- W4312076208 hasOpenAccess W4312076208 @default.
- W4312076208 hasPrimaryLocation W43120762081 @default.
- W4312076208 hasRelatedWork W1868923609 @default.
- W4312076208 hasRelatedWork W1966009219 @default.
- W4312076208 hasRelatedWork W1976608269 @default.
- W4312076208 hasRelatedWork W2043625875 @default.
- W4312076208 hasRelatedWork W2097392642 @default.
- W4312076208 hasRelatedWork W2491451478 @default.
- W4312076208 hasRelatedWork W2977673320 @default.
- W4312076208 hasRelatedWork W3010056926 @default.
- W4312076208 hasRelatedWork W3022986877 @default.
- W4312076208 hasRelatedWork W3202635155 @default.
- W4312076208 isParatext "false" @default.
- W4312076208 isRetracted "false" @default.
- W4312076208 workType "article" @default.